Top Markets
Coin of the day
Brickell Biotech, Inc. Brickell Biotech, Inc.

Brickell Biotech, Inc.

BBI
Peringkat dalam Saham #40377
Brickell Biotech, Inc. is a pharmaceutical company currently in the clinical... Brickell Biotech, Inc. is a pharmaceutical company currently in the clinical development phase, dedicated to creating prescription medicines for various debilitating conditions, including autoimmune and inflammatory disorders, primarily within the United States. Its product pipeline includes sofpironium bromide, which has successfully finished Phase III clinical trials for treating excessive underarm sweating (primary axillary hyperhidrosis). Other notable candidates are BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent stimulator of interferon genes (STING) inhibitor, being explored for autoinflammatory and rare genetic illnesses. The company is also advancing next-generation kinase inhibitors. Brickell Biotech collaborates with several partners, such as Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. Established in 2009, its main office is located in Boulder, Colorado.
Harga Saham
$2.35
Terakhir disinkronkan: 2022-09-07
Kapitalisasi Pasar
$162.94K
Perubahan (1 hari)
2.17%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Brickell Biotech, Inc. (BBI)

Kategori

Jumlah saham beredar untuk Brickell Biotech, Inc. (BBI)
Jumlah saham beredar per August 2026: 0
Menurut laporan keuangan terbaru dan harga saham Brickell Biotech, Inc., jumlah saham beredar saat ini adalah 0. Pada akhir August 2026, perusahaan memiliki 0 saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk Brickell Biotech, Inc. (BBI) dari 2026 hingga 2026
Saham beredar pada akhir setiap tahun
Tahun Saham Beredar Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Saham beredar untuk perusahaan serupa atau pesaing
Perusahaan Saham Beredar Perbedaan Negara
253.90M -
US
62.19M -
NL
- -
CH
- -
KR
0.00 -
BE